Insight
How Niramai AI tech changes the breast cancer detection mission

Corporations Can Close the Gap on Women’s Breast Cancer Screening; in an exclusive report by Gil Bashe, editor-in-chief of Medika Life, FINN Partners’ chair of global health and purpose
March marks Women’s History Month — a time to reflect on the progress and work to be done.
In the realm of medicine, women’s health has long lagged behind men’s, with breast cancer and heart disease diagnoses standing out as two glaring examples of this disparity.
Despite advances in medicine, a hidden and often overlooked challenge persists: the underdiagnosis of breast cancer in women with dense breast tissue.
The Challenge of Dense Breast Tissue
Dense breast tissue is not rare — it affects approximately 40–50 per cent of women.
The condition is characterised by a higher proportion of glandular and fibrous tissue than fatty tissue.
Tissue density increases the risk of developing breast cancer and makes tumors more difficult to detect using traditional mammography.
Mammograms can detect around 90 per cent of breast tumors in the least dense breasts but just 60 percent in the most dense breasts — this dangerous “masking effect” leads to delayed diagnoses and poorer outcomes.
The need for better screening tools for women with dense breast tissue is apparent. Early detection of breast cancer is crucial for improving survival rates.
When cancer is identified at an early stage, treatment options are more effective and less invasive, leading to better patient outcomes.
Research shows that regular screening mammography reduces breast cancer deaths by at least 20 per cent.
However, for women with dense breast tissue, the limitations of mammography call for alternative screening methods to ensure early and accurate detection.
A Personal Mission to Save Lives
Dr. Geetha Manjunath, the founder and CEO of Niramai Health Analytix, didn’t begin her career in healthcare — she’s a computer scientist.
But a devastating personal experience altered her path. Two of her relatives — just 42 and 38 — were diagnosed with late-stage breast cancer and passed away within six months.
Seeing firsthand the emotional, social, and economic toll pushed her to find a better solution.
“I knew there had to be a better way,” Dr. Manjunath reflects. And she found it by combining artificial intelligence and thermal imaging.
This is the potential power of AI applications – not artificial intelligence – but rather “augmented implementation.”
AI + Thermal Imaging = Early Detection
The Niramai innovative screening method, Thermalytix, uses AI to analyse thermal variations in breast tissue.
Unlike mammograms, this approach doesn’t require radiation, is pain-free, and can detect cancers in stage 0 or stage 1—well before a lump can be felt in self-exam or during a routine health professional visit.
The test is simple: a woman sits in front of a thermal camera, and the AI-driven system analyses the heat patterns in her breast tissue.
The system combines thermal radiomics and vascular radiomics to identify potential cancerous anomalies with remarkable accuracy.
Clinical studies have shown that Thermalytix has a false negative rate of less than 5 per cent.
Compare that to the 50 percent false negative rate of mammograms in dense tissue, and the potential for saving lives becomes pressing.
This technology is FDA-cleared, portable and easy to use—it can be set up in a corporate office or rural clinic and requires only 10–15 minutes per screening.
The test is noninvasive and entirely private: no touch, no see, no physical discomfort—just actionable information.
The results are analysed by AI and reviewed by a health professional, with detailed reports emailed directly to the patient within a day.
While it does not replace mammography, a health professional can now visualise tissue activity variations across the breast region, even in dense breasts.
Bringing Screening to the Workplace
In a game-changing move, Niramai is now conducting corporate-hosted breast health screenings in the US — the first of its kind.
This initiative has the potential to expand access to early detection dramatically.
A single device can screen approximately 30 women per day, and because the test is quick, private, and comfortable, participation rates are expected to increase.
FINN Partners, a global communication agency, became one of the first testing sites for this breakthrough technology.
The agency already has several programmes geared to support employee health, and knowing the heightened cancer risks associated with women with dense breast tissue, it partnered with Niramai to provide screening to employees and family members interested.
“We have come a tremendous way in leveraging technology to advance health, yet we must continue to educate on the importance of preventative medicine and screenings,” said Shannon Riggs, managing partner of FINN Portland, who advocated for the in-house screen program.
Unlike a traditional mammogram, the Niramai test is non-contact, radiation-free, and suitable for women of all ages — including those with dense breast tissue.
Niramai technology is portable, making it ideal for deployment not only in hospitals and imaging centers but also in rural areas and underserved communities where access to traditional screening tools is limited.
Overcoming Obstacles to Early Detection
Women with dense breast tissue require supplementary imaging tests, such as ultrasound or MRI, to detect abnormalities that mammograms might miss.
However, accessing these additional screenings presents real challenges:
- Limited Access: Not all healthcare facilities offer advanced imaging technologies like MRI or ultrasound, especially in rural or underserved areas.
- High Costs: Supplementary screenings can be expensive, and insurance coverage varies, leading to potential out-of-pocket expenses for patients.
- Scheduling Delays: High demand for specialised imaging can result in long wait times, delaying diagnosis and treatment.
- Discomfort and Invasiveness: Some women may find additional imaging procedures uncomfortable or invasive, deterring them from pursuing necessary screenings.
Niramai AI-driven technology removes these obstacles by providing an affordable, portable, and non-invasive alternative.
Its ease of use and high accuracy mean more women can access early detection without the hassle and cost associated with additional imaging.

Speaking to Women — Lisa Heathman’s Story
Lisa Heathman knows firsthand the importance of early detection — and how a twist of fate can change everything.
Lisa was healthy and active when a cycling accident left her with broken ribs and pain in her chest. That injury led her to undergo imaging, which revealed a tumour.
It was early-stage breast cancer — detected before symptoms would have otherwise shown up.
Lisa’s story underscores how early detection can save lives. However, not every woman will experience a lucky accident that leads to a diagnosis.
“That’s why tools like Niramai AI-based screening are so critical — they enable women to take control of their health before symptoms appear.
“Dense breast tissue is like a mask,” Lisa explains. “Mammograms couldn’t see through it. But my accident and an MRI saved my life.”
Niramai AI-driven technology lifts that mask — giving women the advantage of catching cancer early, regardless of breast density.
Empowering Women, Saving Lives
Niramai is more than just a technological breakthrough—it’s a tool for health access. Traditional screening methods have long underserved women with dense breast tissue.
Thermalytix closes that gap, giving women of all ages and tissue types a better shot at early detection and survival.
Dr Manjunath’s mission is ambitious but clear: “My vision is to take this test to every woman on earth and eliminate deaths from breast cancer.”
As we observe Women’s History Month, Niramai innovation is a testament to technology’s power to reshape health outcomes.
Early detection saves lives — and thanks to AI, that life-saving tool is now more accessible than ever.
The future of women’s health is digital, and Niramai is leading the way. The question is no longer whether this technology can make a difference—it already does.
The real question is, how can people’s workplace evolve into a convenient point of care?
Insight
Black women want more accessible breast cancer screening info, study finds

Black women in the UK want clearer, more accessible breast cancer screening information, research has found.
The study looked at why Black African and Black Caribbean women are less likely than white women to attend breast screening.
Researchers at the University of Surrey held focus groups and interviews with 47 Black African and Black Caribbean women aged 50 to 71.
Women in this age group are routinely invited for NHS breast screening.
The researchers said only 45 per cent of Black women attend screening, compared with 63 per cent of white women.
Anietie Aliu, lead author, postgraduate researcher at the University of Surrey and registered nurse, said: “Diagnosing breast cancer early can dramatically improve a person’s chance of survival.
“Breast cancer screening plays an important role in this by identifying the cancer and ensuring a person receives speedy treatment.
“Despite the importance of screening, Black women are less likely to attend appointments than white females.
“This puts them at risk of a potential cancer being diagnosed late and spreading to other areas of the body. We need to understand what is preventing Black women from attending these appointments and help identify ways to remove such barriers.”
The study found a need to increase awareness of breast cancer screening, especially among women less familiar with the service.
Some women, particularly those born outside the UK, knew little about breast screening before receiving their first invitation.
Others questioned why they needed screening when they had no symptoms.
The importance of trusted conversations was also identified.
Researchers found that some Black women expected their GPs to speak to them about breast screening, particularly before they reached screening age.
Although NHS breast screening is organised through national screening services, researchers said GPs often have established relationships with patients and may be well placed to offer brief advice on preventive care, including breast screening.
Participants called for stronger links between GP practices, breast screening services and Black community champions.
They said this could help women receive trusted information, ask questions and feel reassured.
Faith and religious beliefs also shaped decisions for some women.
Some Black African Christian women said illness, including cancer, was not permitted by God in their bodies, while others saw screening as a personal choice that did not conflict with Christian faith.
Muslim women highlighted the importance of being able to state their religion on medical appointment forms to help ensure they were seen by a female mammographer.
A mammographer is a healthcare professional trained to carry out breast screening scans.
Aliu added: “Breast screening can save lives, but our findings show that attendance is shaped by multiple factors, not just awareness, although awareness remains important.
“Women need relatable screening information, reassurance, flexible appointments and services that are accessible within their communities.
“Many felt that invitation letters were too formal, and that leaflets and media imagery did not reflect them, making it harder to relate to screening.”
Dr Afrodita Marcu, senior research fellow at the University of Surrey and member of the research team, said: “We need a more collaborative approach, where primary care, screening services and community voices work together to support women before, during and after the invitation.”
The researchers said future breast screening interventions should be designed with Black women, rather than for them.
They said user-friendly and culturally relevant resources, developed with communities, healthcare professionals and screening services, could improve understanding, reduce fear and make breast screening feel more accessible and reassuring.
Dr Robert Kerrison, associate professor of cancer care at the University of Surrey, said: “There is no question that breast screening can be lifesaving, but we need to make it easier for women to understand, access and feel reassured by the programme.
“This means improving communication, addressing practical barriers and making sure healthcare professionals and community partners are supported to provide clear and trusted information.”
The team has also explored healthcare professionals’ perspectives and worked with stakeholders to develop user-friendly materials with Black women.
Researchers said this co-designed approach could help ensure breast screening messages are culturally relevant, practical and shaped by the people they are intended to support.
Insight
“Women’s voices should be heard and pain should never be ignored,” says Wales’s first Women’s Health Minister

Women’s pain should not simply be endured, Wales’s first women’s health minister has said.
Delyth Jewell said she was determined to tackle the normalisation of pain in women’s healthcare and ensure women’s voices are listened to.
Speaking during a Women’s Health Summit at the Temple of Peace on Thursday, July 16, she said: “For too long, women’s health has been treated as an afterthought. No woman should be afraid to speak up about pain or things that don’t feel right.
“Women should be believed about their bodies, and I am determined to change the culture that has let too many women down.”
She added: “Women’s voices helped create the Women’s Health Plan. Now we’re making sure those voices continue to shape what comes next.”
The summit brought together clinicians, researchers and women with lived experience to tackle the normalisation of pain in healthcare and identify how women’s voices can better shape NHS services.
Lived experience means insight from people who have personally gone through a health issue or used healthcare services.
The event focused on pain linked to clinical procedures and long-term health conditions, drawing on research evidence, clinical expertise and women’s personal experiences.
Following the summit, minimum standards for service user engagement will be drafted to ensure women’s voices continue to influence the delivery and future priorities of the Women’s Health Plan.
Service user engagement means involving people who use health services in decisions about how care is designed, delivered and improved.
Work will also begin to refresh and strengthen the plan, including gathering feedback directly from women across Wales.
The NHS Wales Women’s Health Plan was developed after discovery work in 2022, when women across Wales shared their experiences of healthcare.
Many said they had not felt listened to, had symptoms dismissed or had lived with pain for years before receiving a diagnosis.
Insight
The Healthcare AI Playbook: What it actually takes to build trustworthy AI for care

Hosted by Amanda Ducach, CEO, and Morgan Rose, chief science officer, EmaEQ
Healthcare companies have spent the last two years hearing the same advice: get AI into your product. Few have been told what that actually takes.
Most default to the fastest option. Plug in a general-purpose model, wrap it in a chat window, and call the box checked. It looks like progress on a roadmap slide. It rarely holds up once a real patient is on the other end of it.
We’ve spent years building AI specifically for healthcare, and the lesson that keeps repeating itself is simple: accuracy is not the same thing as trust, and trust isn’t something you bolt on after launch. It has to be part of how the system is built from the first line of code, not a feature added once regulators or users start asking questions.
That distinction is the whole reason clinical accuracy gets treated as a checkbox instead of a discipline. A model can sound confident and still be wrong in ways that matter enormously in a health context.
Knowing the difference, and building for it deliberately, is what separates AI that’s genuinely safe for care from AI that’s simply fast to ship.
On July 20th, we’re hosting a live conversation about exactly this: what companies should be paying attention to before they choose an AI to build with, what clinical accuracy really requires, and the pillars we hold every AI system to before it gets anywhere near a patient’s care.
The Healthcare AI Playbook Webinar: July 20th, 1:30-2pm EST, live on LinkedIn.
Register here: https://www.linkedin.com/events/7482643171823509504?viewAsMember=true
If your team is building anywhere near healthcare, or evaluating what’s already in your product, this is the conversation we think the industry needs right now.
Diagnosis2 weeks agoTwo “gamechanger” tests set to speed up endometriosis diagnosis on the NHS
Fertility2 weeks agoWomen with PMOS should have annual NHS checks, new guidance says
News3 days agoNew menopause drug approved for use by NHS in Scotland
Cancer1 week agoThousands of women could avoid painful cancer exam with new AI blood test
Entrepreneur1 week agoApplications open for the third W Accelerate with Merck KGaA and M Ventures
Fertility2 weeks agoOlder women face lower chance of fertility treatment working, even with donor eggs, study finds
News1 week agoWe built Ema like a nurse: Here’s why that matters
News2 weeks agoExperts call for regulation of toxic period product chemicals













